Interventional Glaucoma

Joseph Panarelli, MD, and Arsham Sheybani, MD, discuss the Primary Trabeculectomy for Advanced Glaucoma: Pragmatic Multicentre Randomized Controlled Trial, or TAGS trial, and how this can apply to real world situation. This multicenter randomized controlled trial evaluated whether primary trabeculectomy or primary medical treatment leads to improved outcomes in terms of quality of life, clinical effectiveness, and safety.

Investigators from the New York University Grossman School of Medicine presented data at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation, and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

Kevin Waltz, a consultant for ViaLase, discusses the company's technology: an image-guided femtosecond laser surgical system for the treatment of glaucoma.

Ophthalmologists have seen a progression in cyclophotocoagulation (CPC), with each generation becoming more doctor and patient friendly. Shan C. Lin, MD, a glaucoma specialist at the Glaucoma Center of San Francisco in California, described the advances in the technology.

Tom Frinzi, executive chairman of ViaLase, a new company based in Orange County, gives an update on the company, sharing some exciting new things happening.

The glaucoma market seems to be in an expansion phase, as evidenced by the explosions in the number of new pharmaceutical and surgical options entering the marketplace. The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market.

About 65% of patients sought follow-up care for glaucoma after presentation to the Wills Eye Hospital emergency room (ER), according to Elliot G. Cherkas, BSc, the lead author of the study.

Orbis' Nicolas Jaccard, PhD, principal AI architect, discusses the impact that AI can have on health care, including current applications for AI in glaucoma, the challenges of acceptance of AI in clinical settings, how AI has helped with the diagnosis of glaucoma, and the vision for the future of AI in glaucoma and eye care in general.

NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470

Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.

Device demonstrates potential as a durable, sustained-release glaucoma therapy

The company announced the expansion of its commercial rollout of its MIGS implant to the UK

A University of Houston study found that minorities have fewer eye exams, higher instances of disease.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.

The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.

Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Drug is prescribed as adjunctive therapy for those with glaucoma

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

A complete understanding can help ophthalmologists get better results for their patients.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”